• By ICR Secretariat
  • Posted Thursday, July 8, 2021

GSK returns to brain drugs with major biotech deal


  • GlaxoSmithKline said Friday it will pay at least $700 million for rights to two experimental drugs for neurodegenerative diseases, a deal that could be seen as momentous for the U.K. pharmaceutical giant, which hasn't significantly invested in brain drugs in more than a decade.